Same-day chemotherapy boosts cancer vaccine responses in preclinical models
Both the clinical effects and the unpleasant side effects of chemotherapies, from hair loss to mouth sores to gastrointestinal discomfort, stem from their indiscriminate destruction of cells prone to rapid proliferation. That includes CD8+ T cells, the body's frontline soldiers against viral infections and cancer, which multiply furiously when they're activated by their target antigens.
A recent study published in Cancer Cell reveals that the combination of carboplatin and paclitaxel (CarboTaxol), cyclophosphamide, and anti-PD-1 immune checkpoint blockade (ICB) can enhance the efficacy of cancer vaccines in preclinical models. The researchers discovered that these chemotherapies can directly modulate key functional traits of CD8+ T cells, enabling a better response to subsequent vaccination and possibly anti-PD-1 ICB as well.
This finding suggests that the timing of chemotherapy administration in conjunction with cancer vaccines may synergize to improve tumor control and extend survival in cancer patients.
Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
